Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1891 to 1905 of 7682 results

  1. Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868

    Awaiting development [GID-TA11361] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]

    Awaiting development [GID-TA11300] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Edaravone for treating amyotrophic lateral sclerosis TS ID 11869

    Awaiting development [GID-TA11362] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Epilepsies in children, young people and adults (extraordinary review)

    In development [GID-NG10378] Expected publication date: TBC

    NICE guideline
    In development

  5. Lenacapavir for treating multidrug resistant HIV-1 ID6196

    Suggested remit: To appraise the clinical and cost effectiveness of lenacapavir within its marketing authorisation for treating multidrug resistant HIV-1 for wh...

    Technology appraisal guidance
    Topic selection

  6. Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]

    In development [GID-TA11160] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Elexacaftor–tezacaftor–ivacaftor with ivacaftor for treating cystic fibrosis without an F508del mutation and with a mutation in the CFTR gene that is responsive to elexacaftor–tezacaftor–ivacaftor in people aged 6 and over TS ID 11847

    Awaiting development [GID-TA11372] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Durvalumab with tremelimumab for treating limited-stage small-cell lung cancer after chemoradiation [ID5097]

    Awaiting development [GID-TA11214] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]

    In development [GID-TA10024] Expected publication date: 28 June 2017

    Technology appraisal guidance
    In development

  10. Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]

    In development [GID-TA10606] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Speedboat Inject for endoscopic submucosal dissection of lower gastrointestinal lesions

    Awaiting development [GID-MT602] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  12. The Sonata Treatment - Transcervical Radiofrequency Fibroid Ablation using Intrauterine Ultrasound

    Awaiting development [GID-MT603] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  13. Ondansetron for treating alcohol-use disorder TS ID 11884

    Awaiting development [GID-TA11375] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Canagliflozin for treating type 2 diabetes in people 10 to 17 years TS ID 11888

    Awaiting development [GID-TA11377] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-NG10404] Expected publication date: TBC

    NICE guideline
    In development